Necrotising Fasciitis Explained by a UK Consultant Microbiologist FRCPath Exam Guide
The dangerous feature of necrotising fasciitis is not just how rapidly it kills, but how easily it can look unimpressive at the start. A patient may arrive with “cellulitis”, severe pain, mild erythema and a fever. A few hours later, they may be in septic shock with multi-organ failure and a limb that is no longer viable.
From a microbiology perspective, this is one of the clearest examples of a disease where laboratory precision matters, but clinical urgency matters more. The diagnosis is primarily clinical and surgical. The microbiologist’s role is to support early recognition, advise empiric and directed antimicrobials, process critical specimens fast, and help the multidisciplinary team understand the likely organisms and toxin-mediated complications.
For FRCPath Medical Microbiology part 2, necrotising soft tissue infection is a high-yield topic because it brings together clinical judgement, Gram stain interpretation, blood culture significance, antimicrobial strategy, infection source control, toxin suppression, and communication with surgeons, intensivists and infection specialists.
What necrotising fasciitis means in clinical practice
Necrotising fasciitis is a severe infection of the deep soft tissues, especially the fascia and subcutaneous tissue, with rapid tissue necrosis. Muscle may be spared early, which is one reason the term differs from myonecrosis. As infection spreads along fascial planes, thrombosis of small blood vessels causes ischaemia, necrosis, systemic inflammation and sepsis.
The clinical significance lies in four facts.
It progresses quickly.
The visible skin changes may lag behind deep tissue destruction. Pain out of proportion to examination is a classic warning sign because fascial inflammation and ischaemia may be advanced before the skin looks frankly necrotic.
It requires surgical source control.
Antibiotics alone are inadequate when devitalised tissue and thrombosed vessels limit antimicrobial penetration. Early operative exploration can be both diagnostic and therapeutic.
It is often toxin-mediated.
Group A streptococcus and Staphylococcus aureus can cause systemic toxicity that is disproportionate to local findings. This matters because protein synthesis inhibitors, such as clindamycin or linezolid, may reduce toxin production.
Mortality remains high despite modern care.
Outcome depends heavily on time to diagnosis, time to debridement, comorbidity, site of infection, organism, shock at presentation and adequacy of repeat surgery. Delay in surgical intervention is consistently associated with worse outcomes in observational studies and reflected in international guidance on necrotising soft tissue infection.
Terms used in practice overlap. “Necrotising fasciitis”, “necrotising soft tissue infection” and “NSTI” may appear in the same case. For an exam answer, define the anatomical process clearly and then classify by microbiology, site and host risk.
The organisms that cause necrotising soft tissue infection
A useful FRCPath approach is to classify cases into polymicrobial, monomicrobial streptococcal or staphylococcal, and specific environmental or clostridial syndromes. Real cases do not always fit neatly, but this framework helps with empiric treatment and laboratory interpretation.
Pattern | Common organisms | Typical setting | Microbiology point |
Polymicrobial infection | Enterobacterales, anaerobes, streptococci, enterococci, sometimes Pseudomonas aeruginosa | Diabetes, peripheral vascular disease, perineal infection, post-operative infection, abdominal source | Mixed Gram stain and mixed culture are significant if from deep tissue |
Group A streptococcal infection | Streptococcus pyogenes | Minor trauma, varicella, childbirth, injection drug use, otherwise healthy host | May produce severe toxin-mediated disease and streptococcal toxic shock |
Staphylococcal infection | Staphylococcus aureus, including MRSA where risk factors exist | Skin trauma, abscess, healthcare exposure, injection drug use | Consider PVL-associated strains in recurrent abscess or severe skin disease |
Clostridial infection | Clostridium perfringens, other clostridia | Trauma, devitalised tissue, bowel source, injection drug use | Gas, haemolysis and myonecrosis suggest clostridial disease |
Marine or freshwater exposure | Vibrio vulnificus, Aeromonas hydrophila | Seawater, shellfish exposure, freshwater injury | Important travel and exposure history changes empiric cover |
Polymicrobial necrotising infection
Polymicrobial disease, sometimes called type I necrotising fasciitis, often involves a mixture of facultative anaerobes and strict anaerobes. The synergy between organisms matters. Facultative organisms consume oxygen and create conditions in which anaerobes thrive. Anaerobes produce enzymes and toxins that contribute to tissue destruction.
This pattern is common in:
Fournier’s gangrene
diabetic foot infection
pressure ulcer-associated infection
post-operative wound infection
infection arising from bowel, genitourinary or perineal sources
From the laboratory perspective, mixed growth from a superficial swab is hard to interpret. Mixed growth from deep operative tissue, especially with organisms seen on direct Gram stain, is clinically meaningful.
Group A streptococcus
Healthcare teams often remember S. pyogenes because it can cause fulminant disease after trivial trauma. It remains susceptible to penicillin in routine clinical practice, but penicillin alone is not enough in severe toxin-mediated infection.
Clindamycin is used because it inhibits protein synthesis. Its theoretical and clinical value includes:
suppression of streptococcal toxin production
activity independent of bacterial growth phase
avoidance of the “Eagle effect”, where high bacterial inocula may reduce beta-lactam effectiveness in experimental settings
In suspected group A streptococcal necrotising infection, the combination of a beta-lactam plus clindamycin is the standard principle. If clindamycin resistance is found or strongly suspected, linezolid may be discussed as an alternative toxin-suppressing agent, guided by local policy and specialist advice.
Staphylococcus aureus
S. aureus may be isolated alone or as part of mixed infection. MSSA should be covered by standard broad-spectrum empiric regimens, but MRSA cover should be added if risk factors exist or local epidemiology supports it.
Risk factors that may push empiric MRSA cover include:
previous MRSA colonisation or infection
recent healthcare exposure
severe infection in an area with significant MRSA rates
injection drug use
known outbreak or colonisation pressure
PVL-producing S. aureus is not diagnosed by routine culture alone. It is suspected from the clinical pattern, such as recurrent boils, severe necrotising skin infection, or necrotising pneumonia, and confirmed by reference laboratory testing if required.
Clostridial myonecrosis and gas-forming infection
Clostridial infection deserves separate mention because exam stations may test the distinction between necrotising fasciitis and gas gangrene. Clostridium perfringens can cause rapidly progressive myonecrosis, severe pain, systemic toxicity, crepitus and gas in tissues. Intravascular haemolysis may occur.
On Gram stain, large Gram-positive rods with few inflammatory cells can be an important clue, particularly if the clinical history includes trauma, devitalised tissue or bowel contamination. Treatment requires urgent surgery, high-dose beta-lactam therapy, clindamycin for toxin suppression, and broad cover until the full picture is clear.
Vibrio and Aeromonas
Exposure history can transform management. Vibrio vulnificus sepsis and necrotising wound infection may follow seawater exposure or handling seafood, especially in people with chronic liver disease or iron overload. Aeromonas hydrophila is associated with freshwater exposure and traumatic wounds.
These organisms may not be reliably covered by standard Gram-positive focused regimens. A strong answer should mention early discussion with microbiology and tailoring empiric therapy to the exposure. Doxycycline-based combinations are often used for suspected Vibrio vulnificus, while fluoroquinolones or third-generation cephalosporins may feature in regimens for Aeromonas, depending on local susceptibility and policy.
How to recognise necrotising fasciitis at the bedside
Laboratory tests rarely make the diagnosis alone. The best microbiology advice begins with knowing when the clinical picture is dangerous.
Clinical features that should trigger urgent surgical review include:
severe pain, especially pain out of proportion
rapidly progressive erythema, swelling or skin discolouration
systemic toxicity, hypotension or confusion
tenderness extending beyond visible erythema
bullae, ecchymosis, necrosis or anaesthesia of the skin
crepitus, although absence of crepitus does not exclude the diagnosis
failure to respond to appropriate cellulitis treatment
high-risk host features, such as diabetes, immunosuppression, vascular disease or recent surgery
The classical late findings, such as purple skin, bullae and frank necrosis, are helpful when present but dangerous to wait for.
What the LRINEC score can and cannot do
The Laboratory Risk Indicator for Necrotising Fasciitis score uses routine blood tests such as C-reactive protein, white cell count, haemoglobin, sodium, creatinine and glucose. It was developed to help distinguish necrotising infection from other soft tissue infections.
For exam purposes, the key point is limitation. LRINEC may support concern, but a low score does not safely exclude necrotising fasciitis. Early disease, immunosuppression, atypical organisms and prior antibiotics can all blunt laboratory patterns. Clinical suspicion and surgical assessment override scoring systems.
Imaging is useful only if it does not delay theatre
CT or MRI may show fascial thickening, fluid tracking, gas, non-enhancement, abscess or deep extension. Ultrasound may show fluid collections or gas artefact but is less definitive.
Imaging is appropriate when:
the diagnosis is uncertain
the patient is stable enough
imaging can be obtained immediately
results will change the surgical approach
If the patient has shock, rapidly progressive disease or clear signs of necrotising infection, imaging should not delay operative exploration.
A common FRCPath viva trap is to overstate the role of the lab or imaging. The safer answer is:
Necrotising infection is a clinical and surgical emergency. Take blood cultures and deep tissue samples, start broad-spectrum antibiotics immediately, and do not delay source control for laboratory confirmation.
What the microbiology laboratory should do
The laboratory contribution starts before a specimen reaches the bench. The microbiologist should advise the clinical team on the right specimens, the urgency of transport and the information needed on the request form.
The best specimens are deep tissues and fluids
Preferred samples include:
deep operative tissue from the fascial plane
pus or fluid aspirated from a deep collection
tissue from the edge of necrotic and viable areas
blood cultures before antibiotics if this does not delay treatment
swabs only if no better sample is available
Superficial swabs are often misleading. They may reflect colonising skin or mucosal flora rather than invasive pathogens. In Fournier’s gangrene, for example, superficial swabs may grow mixed enteric flora that tells little about which organisms are driving the necrotising process.
For operative samples, the request should state “suspected necrotising fasciitis” or “necrotising soft tissue infection”, the anatomical site, antibiotic exposure, comorbidities, relevant travel or water exposure, and whether clostridial infection is suspected. This prompts urgent microscopy and appropriate aerobic and anaerobic culture.
Direct microscopy can guide immediate treatment
A Gram stain from deep tissue or fluid can provide same-day information. Useful patterns include:
Gram-positive cocci in chains, suggesting streptococci
Gram-positive cocci in clusters, suggesting staphylococci
mixed Gram-positive and Gram-negative organisms, suggesting polymicrobial infection
large Gram-positive rods, suggesting clostridia or other anaerobic rods
curved Gram-negative rods in the right exposure context, raising concern for Vibrio
Microscopy should be interpreted with clinical context. A heavy neutrophil response supports infection, but clostridial myonecrosis may show surprisingly few inflammatory cells because of toxin-mediated tissue destruction.
Culture and identification
Routine processing usually includes aerobic and anaerobic culture. Laboratories may use enriched media such as blood agar, chocolate agar, MacConkey agar and anaerobic plates or broths, depending on local protocols and specimen type.
Modern UK clinical microbiology laboratories commonly use MALDI-TOF mass spectrometry for rapid organism identification once colonies grow. This can shorten the time from culture positivity to organism name, but susceptibility results still need appropriate testing.
Blood cultures are important because bacteraemia supports invasive disease and may turn positive before tissue culture is finalised. S. pyogenes, S. aureus, Enterobacterales, anaerobes or clostridia in blood cultures should be treated as clinically significant in this context.
Susceptibility testing and resistance issues
Susceptibility testing should guide narrowing once the patient stabilises and surgical source control is underway. Key resistance questions include:
Is S. aureus MRSA or MSSA?
Is clindamycin resistance present in group A streptococcus or staphylococcus?
Are Enterobacterales producing ESBL or other beta-lactamases?
Is Pseudomonas aeruginosa present?
Are anaerobes likely covered by the chosen regimen?
Does the isolate require reference laboratory confirmation?
For group A streptococcus, laboratories may report penicillin susceptibility according to standard expectations, with clindamycin susceptibility tested or inferred according to local methods. If clindamycin resistance is detected, the clinical team should know quickly because toxin suppression is part of the treatment logic.
Molecular tests and reference laboratory support
PCR can be useful in selected cases, especially for toxin genes, outbreak investigation, PVL testing, or confirmation when antibiotics have sterilised cultures. 16S rRNA PCR may detect bacterial DNA in culture-negative deep tissue, although interpretation requires care because contamination and non-viable organisms can complicate results.
Reference laboratories can support:
streptococcal typing in severe invasive group A streptococcal infection
PVL testing for S. aureus
uncommon anaerobe identification
public health investigation if clusters occur
Molecular testing should not delay empiric therapy or surgery. Its value lies in confirmation, epidemiology and refining management.
Treatment principles that matter in the exam and on call
Management rests on four pillars: resuscitation, surgery, antimicrobial therapy and supportive care. The microbiologist influences all four, but surgery is decisive.
Urgent surgical exploration and debridement
Early surgical review is mandatory when necrotising infection is suspected. Operative findings may include grey necrotic fascia, thin “dishwater” fluid, lack of bleeding, loss of normal fascial resistance and easy blunt dissection along tissue planes.
Debridement should remove all non-viable tissue. Repeat operations are common because necrosis can extend after the first procedure. A patient may need re-exploration within 24 to 48 hours, guided by clinical condition and surgical findings. In limb disease, amputation may be life-saving if infection and ischaemia cannot be controlled.
For Fournier’s gangrene, colorectal, urology and plastic surgery teams may all be involved. Source control may include drainage, debridement, urinary diversion, faecal diversion in selected cases, and later reconstruction.
Empiric antibiotics should be broad and immediate
Antibiotics should be given as soon as cultures are taken, provided cultures do not delay treatment. A typical UK empiric approach aims to cover:
group A streptococcus
S. aureus
Gram-negative bacilli
anaerobes
toxin production
MRSA if risk factors or local policy indicate
Exact regimens vary by NHS trust policy, allergy status, renal function, severity and local resistance. A common principle is a broad-spectrum beta-lactam with anaerobic and Gram-negative activity, plus a toxin-suppressing agent.
Examples used in many UK-style discussions include:
piperacillin-tazobactam plus clindamycin
meropenem plus clindamycin in selected high-risk or resistant Gram-negative settings
addition of vancomycin, teicoplanin, daptomycin or linezolid if MRSA cover is needed
gentamicin in some local sepsis regimens, with renal and toxicity considerations
This is informational and not a substitute for local antimicrobial guidance. In an exam, state the principle and then anchor the answer to local policy and specialist review.
Directed therapy once organisms are known
Once culture results return, treatment should narrow where safe.
For proven group A streptococcal necrotising infection, a common directed approach is high-dose intravenous benzylpenicillin plus clindamycin. Clindamycin is often continued during the toxin-mediated phase, with duration guided by clinical response, source control and local policy.
For MSSA, antistaphylococcal beta-lactams are preferred when feasible. For MRSA, therapy depends on susceptibility, infection severity, renal function and whether linezolid is being used for toxin suppression.
For polymicrobial infection, treatment must retain anaerobic and Gram-negative cover until adequate debridement has occurred and the microbiology is clear. Do not narrow too quickly if further necrotic tissue remains.
For clostridial myonecrosis, high-dose penicillin plus clindamycin is a standard principle, alongside aggressive surgery. Broad Gram-negative and anaerobic cover may be needed initially if the source is unclear.
Intravenous immunoglobulin has a limited but recognised role
Intravenous immunoglobulin may be considered in severe streptococcal toxic shock syndrome, particularly with shock and multi-organ failure. Evidence is not as strong as for surgery and antibiotics, and use should involve infection specialists, intensivists and pharmacy because supply, dosing and eligibility are tightly managed.
For FRCPath, the best answer is balanced: IVIG is not routine for all cases, but it may be discussed in severe invasive group A streptococcal disease with toxic shock, alongside definitive source control and antimicrobials.
Supportive care influences survival
Patients often need critical care for:
haemodynamic support
renal replacement therapy
ventilation
correction of metabolic acidosis
glycaemic control
nutrition
pain control
wound management and reconstruction planning
Microbiology input continues after the first phone call. Daily review may be needed to interpret new cultures, adjust antibiotics for renal function, assess clindamycin duration, identify resistant organisms and support infection prevention.
How early recognition improves outcome
The single most useful systems lesson is that suspected necrotising fasciitis should trigger escalation before certainty. Waiting for skin necrosis, gas on imaging or positive cultures costs time.
Early recognition improves outcome because it shortens time to:
senior surgical review
first debridement
active antimicrobial therapy
source control
critical care support
repeat assessment
Several practical behaviours make a difference.
Use the phrase “suspected necrotising soft tissue infection”.
This wording carries urgency. It tells surgeons, theatres, intensive care and the lab that this is not uncomplicated cellulitis.
Phone the laboratory.
Do not rely only on electronic requests. A direct call allows urgent Gram stain, anaerobic culture and escalation of positive blood cultures.
Ask for the exposure history early.
Seawater, freshwater, animal bites, injection drug use, recent surgery, childbirth, varicella, travel and liver disease all change the differential.
Do not be reassured by one normal result.
Normal sodium, modest CRP or absent gas on imaging does not exclude early disease.
Review the patient repeatedly.
Necrotising infection declares itself over time. Serial examination by the same team can reveal progression that a single assessment misses.
FRCPath part 2 exam approach
A strong exam answer should be structured, safe and decisive. The examiner is looking for prioritisation as much as factual recall.
If given a clinical vignette
Start with the diagnosis and urgency.
A suitable opening might be:
This is suspected necrotising soft tissue infection with sepsis. I would advise immediate senior surgical review for exploration and debridement, take blood cultures and deep tissue samples, and start empiric intravenous antibiotics without delay.
Then work through:
Assess severity and resuscitation needs
Involve surgery, intensive care and microbiology
Take correct specimens
Start broad empiric antibiotics with toxin suppression
Interpret Gram stain and early culture
De-escalate when safe
Consider public health or reference testing where relevant
If shown a Gram stain
Describe what is visible before naming the organism. For example:
“Gram-positive cocci in chains from deep tissue, consistent with streptococci in this context”
“Large Gram-positive rods with tissue necrosis, concerning for clostridial infection”
“Mixed Gram-positive cocci, Gram-negative rods and anaerobic-looking flora, supporting polymicrobial necrotising infection”
Then state the management implication. Gram-positive cocci in chains in a septic patient with severe soft tissue infection should prompt beta-lactam plus clindamycin and urgent source control, not passive waiting for final identification.
If asked about antibiotics
Avoid giving a single memorised regimen without context. State that treatment follows local guidance, then give the coverage required. Include MRSA and unusual water-associated organisms when risk factors exist.
A concise answer could say:
broad-spectrum beta-lactam for streptococci, Gram-negatives and anaerobes
clindamycin or another protein synthesis inhibitor for toxin suppression
MRSA agent if risk factors or local epidemiology indicate
narrow once cultures, susceptibilities and operative findings allow
If asked about duration
There is no single universal duration. It depends on source control, organism, bacteraemia, clinical response and further debridement. Antibiotics usually continue until the patient has improved clinically, no further debridement is needed, and systemic signs have settled. Bacteraemia, endocarditis, osteomyelitis or prosthetic infection changes the duration.
Common pitfalls to avoid
Several mistakes recur in real practice and exam answers.
Calling it cellulitis despite red flags.
Severe pain, shock, rapid progression and skin anaesthesia should override a benign early appearance.
Waiting for imaging.
CT can help, but theatre should not wait in an unstable patient with convincing signs.
Sending only a superficial swab.
Deep tissue is the key specimen. Swabs are a poor substitute.
Forgetting toxin suppression.
In suspected group A streptococcal or clostridial disease, clindamycin or linezolid is not an optional afterthought.
Failing to reassess antibiotics.
Empiric broad cover is correct at the start. It should not remain unchanged for days without review of cultures, renal function and operative findings.
Ignoring exposure clues.
A seawater wound in a patient with chronic liver disease is a different microbiological problem from post-operative Fournier’s gangrene.
FAQ
What is the most important early clinical clue in necrotising fasciitis?
Pain out of proportion to the visible skin findings is a classic early clue. Rapid progression, systemic toxicity, skin anaesthesia, bullae, ecchymosis and shock also raise concern. Absence of late skin necrosis does not exclude the diagnosis.
Can a low LRINEC score rule out necrotising fasciitis?
No. LRINEC may support suspicion, but it cannot safely exclude early necrotising infection. Clinical assessment and urgent surgical review are more important than the score.
What specimens should be sent to microbiology?
Send blood cultures and deep operative tissue or deep aspirated fluid. State the suspected diagnosis on the request. Superficial swabs are less useful and may reflect colonisation rather than invasive infection.
Why is clindamycin used in group A streptococcal infection?
Clindamycin inhibits protein synthesis and may reduce toxin production. It also retains activity in high-inoculum, stationary-phase infection where beta-lactam activity may be less reliable. It is used with, not instead of, appropriate beta-lactam therapy unless allergy or resistance changes the plan.
When should MRSA be covered empirically?
MRSA cover should be considered when the patient has previous MRSA, relevant healthcare exposure, injection drug use, severe infection in a high-prevalence setting, or local policy recommends it. De-escalate when cultures and susceptibilities allow.
Final takeaway
Necrotising soft tissue infection rewards early decisive action. The safest microbiology advice is clear: take blood cultures and deep tissue samples, start broad intravenous antibiotics with toxin suppression, phone the lab, and push for urgent surgical source control.
For FRCPath part 2 preparation, the strongest answers combine urgency with microbiological precision. Know the organisms, understand the lab pathway, explain why antibiotics alone are insufficient, and show how early recognition changes survival.
For more structured revision built around UK microbiology exam practice, see FRCPath Prep’s Medical Microbiology resources.
Comments